CNK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cinemark Holdings Inc (CNK) is not an ideal buy at this moment for a beginner investor with a long-term strategy. The stock's technical indicators are neutral, financial performance shows declining trends, and recent analyst ratings are mixed. While hedge funds are increasing their positions and there is potential for box office recovery in 2026, the lack of strong positive catalysts and the absence of proprietary trading signals suggest holding off on this investment for now.
The MACD is positive at 0.228 but contracting, indicating weakening momentum. RSI is neutral at 69.809, and moving averages are converging, showing no clear trend. Key support is at 25.84, and resistance is at 28.724. The stock is trading near resistance levels, suggesting limited immediate upside.
Hedge funds are increasing their positions, with buying up 101.37% last quarter. Analysts from Roth Capital and MoffettNathanson have issued buy ratings, citing improved box office trends and a stronger film slate for 2026.
Insider trading shows neutral activity, with no significant trends. Marathon Asset Management has fully exited its position in CNK, citing market volatility concerns. Financial performance in Q4 2025 showed declining revenue (-4.67% YoY), net income (-33.46% YoY), and EPS (-20.59% YoY). Additionally, the CEO plans to sell a significant portion of shares, which could signal a lack of confidence.
Cinemark's Q4 2025 financials reflect a decline in revenue to $776.3M (-4.67% YoY), net income to $33.8M (-33.46% YoY), and EPS to $0.27 (-20.59% YoY). Gross margin slightly improved to 57.63% (+0.03% YoY), but overall performance indicates challenges in growth and profitability.
Analyst sentiment is mixed. Positive ratings from Roth Capital ($36 price target) and MoffettNathanson ($30 price target) highlight optimism for 2026 box office trends. However, Goldman Sachs maintains a sell rating with a $22 price target, citing concerns about sustaining market share and margin expansion. Other analysts like B. Riley and JPMorgan have neutral to slightly positive outlooks with price targets in the $29-$31 range.
